Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ostrich Pharma, also known as B.C. Ostrich Farm, is a Japanese biotechnology company specializing in the development and mass production of ostrich-derived antibodies (IgY). Founded by Dr. Yasuhiro Tsukamoto, the company utilizes the ostrich's robust immune system and large egg size to produce high volumes of antibodies more efficiently and cost-effectively than traditional mammalian systems. Their technology platform is capable of rapidly generating antibodies against a wide range of pathogens, including SARS-CoV-2, influenza, and Ebola. The company's commercial products include antibody-infused face masks for viral protection and specialized skincare lines for conditions like acne and atopic dermatitis. Ostrich Pharma continues to explore therapeutic applications for its IgY technology in infectious diseases and oncology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on B.C. Ostrich Farm.